CANF

← Markets

CANFCan-Fite Biopharma Ltd.

Discussion

Nothing said here yet.

to join the conversation.

—

Mon, Aug 17
6:00 AMYahooCan-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Wed, Aug 12
6:00 AMYahooCan-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Mon, Aug 3
6:00 AMYahooCan-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Mon, Jul 20
6:00 AMYahooCan-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Tue, Jul 14
6:00 AMYahooCan-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Mon, Jul 6
6:00 AMYahooCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Wed, Jul 1
6:00 AMYahooCan-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Fri, Jun 26
6:00 AMYahooCan-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Mon, Jun 22
6:00 AMYahooCan-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Wed, Jun 17
6:00 AMYahooCan-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Tue, Jun 2
6:00 AMYahooCan-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
Mon, May 18
6:00 AMYahooScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market